BRPI0417605B8 - “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”. - Google Patents

“n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.

Info

Publication number
BRPI0417605B8
BRPI0417605B8 BRPI0417605A BRPI0417605A BRPI0417605B8 BR PI0417605 B8 BRPI0417605 B8 BR PI0417605B8 BR PI0417605 A BRPI0417605 A BR PI0417605A BR PI0417605 A BRPI0417605 A BR PI0417605A BR PI0417605 B8 BRPI0417605 B8 BR PI0417605B8
Authority
BR
Brazil
Prior art keywords
ylpyridin
oxoethyl
pyrrolidin
benzamide
pyrimidin
Prior art date
Application number
BRPI0417605A
Other languages
English (en)
Inventor
Qi Han Amy
Wang Anlai
Metcalf Brian
Zheng Changsheng
Xue Chu-Biao
J Robinson Darius
Zhang Yingxin
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of BRPI0417605A publication Critical patent/BRPI0417605A/pt
Publication of BRPI0417605B1 publication Critical patent/BRPI0417605B1/pt
Publication of BRPI0417605B8 publication Critical patent/BRPI0417605B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)

Abstract

derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina. a presente invenção está relacionada com derivados de 3-cicloalquilaminopirrolidina de fórmula i: (na qual r1, r2, r3, r4, r5, r6, r7, x, y, e z são como definido nesta) que são úteis como moduladores da atividade dos receptores de quimiocina. em particular, esses compostos são úteis como moduladores de receptores de quimiocinas e mais especificamente como moduladores dos receptores ccr2 e/ou ccr5. os compostos e composições da invenção podem se ligar aos receptores de quimiocina, por exemplo, os receptores ccr2 e/ou ccr5, e são úteis para o tratamento de doenças associadas a quimiocina, por exemplo, atividade de ccr2 e/ou ccr5, tais como aterosclerose, restenose, lúpus, rejeição ao transplante de órgãos e artrite reumatóide.
BRPI0417605A 2003-12-18 2004-12-16 “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”. BRPI0417605B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53127003P 2003-12-18 2003-12-18
US60/531.270 2003-12-18
PCT/US2004/042321 WO2005060665A2 (en) 2003-12-18 2004-12-16 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

Publications (3)

Publication Number Publication Date
BRPI0417605A BRPI0417605A (pt) 2007-03-27
BRPI0417605B1 BRPI0417605B1 (pt) 2020-05-12
BRPI0417605B8 true BRPI0417605B8 (pt) 2021-05-25

Family

ID=34710216

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417605A BRPI0417605B8 (pt) 2003-12-18 2004-12-16 “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.

Country Status (27)

Country Link
US (5) US7576089B2 (pt)
EP (1) EP1696919B1 (pt)
JP (1) JP4740151B2 (pt)
KR (2) KR20080052683A (pt)
CN (2) CN102344398B (pt)
AP (1) AP2439A (pt)
AU (1) AU2004305079B2 (pt)
BR (1) BRPI0417605B8 (pt)
CA (1) CA2550596C (pt)
CR (1) CR8455A (pt)
DK (1) DK1696919T3 (pt)
EA (1) EA013631B1 (pt)
EC (1) ECSP066615A (pt)
ES (1) ES2439894T3 (pt)
GE (1) GEP20084505B (pt)
IL (1) IL175953A (pt)
IS (1) IS2956B (pt)
MA (1) MA28391B1 (pt)
MX (1) MXPA06007000A (pt)
NI (1) NI200600136A (pt)
NO (1) NO336486B1 (pt)
NZ (1) NZ547316A (pt)
OA (1) OA13338A (pt)
TN (1) TNSN06188A1 (pt)
UA (1) UA82917C2 (pt)
WO (1) WO2005060665A2 (pt)
ZA (1) ZA200604875B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050024A2 (en) 2002-11-27 2004-06-17 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
ES2431524T3 (es) * 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
AP2006003849A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006013427A2 (en) * 2004-07-30 2006-02-09 Pfizer Products Inc. Treatment of ccr2 mediated diseases or disorders
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US8937184B2 (en) * 2005-02-16 2015-01-20 Abbvie B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
MX2009005252A (es) * 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
AR065369A1 (es) 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
RU2481332C2 (ru) * 2007-09-25 2013-05-10 Эбботт Лэборетриз Октагидропенталеновые соединения в качестве антагонистов хемокиновых рецепторов
CN102066359B (zh) * 2008-06-18 2013-08-21 弗·哈夫曼-拉罗切有限公司 杂芳基甲酰胺衍生物
WO2010003240A1 (en) 2008-07-08 2010-01-14 The Royal Institution For The Advancement Of Learning/Mcgill University Gmcsf and truncated ccl2 conjugates and methods and uses thereof
PL2370442T3 (pl) * 2008-11-26 2013-08-30 Pfizer 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny
CA2745969C (en) 2008-12-10 2017-04-25 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
ES2551557T3 (es) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
ES2528625T3 (es) 2009-04-17 2015-02-11 Janssen Pharmaceutica Nv Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2
KR101151415B1 (ko) * 2009-07-10 2012-06-01 양지화학 주식회사 Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
EP2646429B1 (en) 2010-12-01 2014-10-15 Janssen Pharmaceutica NV 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
CN103391931A (zh) * 2011-02-25 2013-11-13 辉瑞有限公司 治疗肝纤维化的方法
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
CN109982914A (zh) * 2016-08-01 2019-07-05 全日设计有限公司 运输设备
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882145A (en) * 1972-12-22 1975-05-06 Ppg Industries Inc Halogenated N-substituted thiocarboxy maleimides
HU175454B (hu) * 1977-07-25 1980-08-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh predel'nykh i chastichno predel'nykh n-acil-pirrol-2,5-dionov
DE4029054A1 (de) * 1990-09-13 1992-03-19 Bayer Ag N-acylpyrrolidin-derivate
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0914319B1 (en) 1996-05-20 2001-11-21 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
HUP0004200A3 (en) 1997-11-18 2001-04-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and their use as drugs
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2000051610A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) * 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU4796700A (en) 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
ATE308985T1 (de) 1999-05-18 2005-11-15 Teijin Ltd Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
AU5600100A (en) * 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
CA2378499A1 (en) 1999-08-04 2001-02-15 Teijin Limited Cyclic amine ccr3 antagonists
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
JP4029960B2 (ja) * 2001-10-05 2008-01-09 独立行政法人理化学研究所 アブシジン酸生合成阻害剤
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2483843A1 (en) * 2002-04-29 2003-11-13 Merck & Co. Inc. Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
JP3780291B2 (ja) 2002-04-29 2006-05-31 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤
AU2003286701B2 (en) 2002-10-30 2008-12-18 Merck Sharp & Dohme Corp. Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
WO2004042351A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
US7514431B2 (en) 2002-10-30 2009-04-07 Merck & Co., Inc. Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
JP2006508948A (ja) 2002-10-30 2006-03-16 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のヘテロアリールピペリジンモジュレーター
AU2003284984B2 (en) 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
WO2004050024A2 (en) * 2002-11-27 2004-06-17 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
RU2317295C1 (ru) 2003-10-27 2008-02-20 Мерк Энд Ко., Инк. Соль антагониста ccr-2
TWI341835B (en) * 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
JP2007519633A (ja) 2004-01-02 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド アルキルアミノ、アリールアミノおよびスルホンアミドシクロペンチルアミド系のケモカイン受容体活性調節剤
EP1732552A4 (en) 2004-01-20 2007-12-19 Merck & Co Inc 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
CN1913778A (zh) 2004-01-28 2007-02-14 默克公司 趋化因子受体活性的氨基环戊基吡啶并吡嗪酮调节剂
EP1742919A4 (en) 2004-04-26 2010-04-28 Merck Sharp & Dohme TETRAHYDROPYRANYL-CYCLOPENTYL-1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROISOCHINOLINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
PA8653301A1 (es) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin

Also Published As

Publication number Publication date
TNSN06188A1 (fr) 2007-11-15
IL175953A (en) 2015-09-24
MXPA06007000A (es) 2006-08-31
US20140155377A1 (en) 2014-06-05
GEP20084505B (en) 2008-10-10
NO336486B1 (no) 2015-09-07
DK1696919T3 (da) 2013-12-09
AP2006003629A0 (en) 2006-06-30
AP2439A (en) 2012-08-31
CN102344398A (zh) 2012-02-08
CN1893945A (zh) 2007-01-10
CA2550596C (en) 2011-03-15
CA2550596A1 (en) 2005-07-07
IS8466A (is) 2006-05-15
IS2956B (is) 2016-12-15
ES2439894T3 (es) 2014-01-27
US8697870B2 (en) 2014-04-15
KR20070008536A (ko) 2007-01-17
IL175953A0 (en) 2006-10-05
NO20063255L (no) 2006-09-14
UA82917C2 (en) 2008-05-26
WO2005060665A3 (en) 2005-12-15
BRPI0417605A (pt) 2007-03-27
KR100859027B1 (ko) 2008-09-17
KR20080052683A (ko) 2008-06-11
ZA200604875B (en) 2007-11-28
US20150231114A1 (en) 2015-08-20
US20050192302A1 (en) 2005-09-01
US20090286792A1 (en) 2009-11-19
EA200600991A1 (ru) 2006-10-27
ECSP066615A (es) 2006-10-25
EP1696919A4 (en) 2009-07-01
CN102344398B (zh) 2015-02-25
JP4740151B2 (ja) 2011-08-03
NZ547316A (en) 2011-01-28
US20170050942A1 (en) 2017-02-23
CR8455A (es) 2007-03-02
AU2004305079B2 (en) 2011-05-12
AU2004305079A1 (en) 2005-07-07
JP2007514751A (ja) 2007-06-07
MA28391B1 (fr) 2007-01-02
NI200600136A (es) 2008-04-24
EP1696919B1 (en) 2013-10-02
US7576089B2 (en) 2009-08-18
EP1696919A2 (en) 2006-09-06
WO2005060665A2 (en) 2005-07-07
HK1166321A1 (en) 2012-10-26
WO2005060665A8 (en) 2006-05-04
EA013631B1 (ru) 2010-06-30
OA13338A (en) 2007-04-13
BRPI0417605B1 (pt) 2020-05-12

Similar Documents

Publication Publication Date Title
BRPI0417605B1 (pt) “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.
SE0501185L (sv) 3-aminopyrrolidinderivat som modulatorer av kemokinreceptorer
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
MA31373B1 (fr) Composes amino-heterocycliques
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
BRPI0312882B8 (pt) derivados de pleuromutilina e composição farmacêutica
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
MXPA05010496A (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EP1765335A4 (en) PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
MXPA04008152A (es) Compuestos azabiciclicos para el tratamiento de enfermedades.
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
BRPI0408248A (pt) derivados azabicìclicos de piridiloximetila e de benzisoxazol
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
EP2077719A4 (en) PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
BR0317383A (pt) Metabólitos agonista de vasopressina biologicamente ativos
ATE400552T1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)- derivate und sie enthaltende zusammensetzungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/44

Ipc: A61K 31/44 (2011.01), C07D 401/12 (2011.01), C07D

Free format text: PARA: INT. CL. A61K 31/44; C07D 401/12, 401/14; A61P 37/00

Ipc: A61K 31/44 (2011.01), C07D 401/12 (2011.01), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: INCYTE CORPORATION (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2701 DE 11-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.